Leader Heartburn Relief (cimetidine) Disease Interactions
There are 4 disease interactions with Leader Heartburn Relief (cimetidine):
Cimetidine (Includes Leader Heartburn Relief) ↔ Liver Disease
Severe Potential Hazard, Moderate plausibility
Applies to: Liver Disease
Cimetidine is partially metabolized by the liver, and to a greater extent when administered orally than when given intravenously. Although dosage reductions are generally not necessary, therapy with cimetidine should be administered cautiously in patients with liver disease. Hepatotoxicity has been associated with cimetidine use. In addition, liver disease appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are usually reversible within 3 to 4 days after discontinuation of therapy.
References
- Taylor DC, Cresswell PR, Bartlett DC "The metabolism and elimination of cimetidine, a histamine H2-receptor antagonist, in the rat, dog and man." Drug Metab Dispos 6 (1978): 21-30
- Grahnen A, Jameson S, Loof L, Tyllstrom J, Lindstrom B "Pharmacokinetics of cimetidine in advanced cirrhosis." Eur J Clin Pharmacol 26 (1984): 347-55
- Gugler R, Muller-Liebenau B, Somogyi A "Altered disposition and availability of cimetidine in liver cirrhotic patients." Br J Clin Pharmacol 14 (1982): 421-30
- Hashimoto F, Davis RL, Egli D "Hepatitis following treatments with famotidine and then cimetidine." Ann Pharmacother 28 (1994): 37-9
- del Arbol LR, Moreira V, Moreno A, et al "Bridging hepatic necrosis associated with cimetidine." Am J Gastroenterol 74 (1980): 267-9
- "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
- Lewis JH "Hepatic effects of drugs used in the treatment of peptic ulcer disease." Am J Gastroenterol 82 (1987): 987-1003
- Delpre G, Kadish U, Livni E "Hepatitis following cimetidine administration." Am J Med Sci 283 (1982): 153-6
- Schwartz JT, Gyorkey F, Graham DY "Cimetidine hepatitis." J Clin Gastroenterol 8 (1986): 681-6
- Bianchi Porro G, Lazzaroni M, Lodola E "Blood levels of cimetidine in patients with liver cirrhosis." Int J Clin Pharmacol Ther Toxicol 21 (1983): 374-7
- Van Steenbergen W, Vanstapel MJ, Desmet V, et al "Cimetidine-induced liver injury: report of three cases." J Hepatol 1 (1985): 359-68
- Boyd PT, Lepre F, Dickey JD "Chronic active hepatitis associated with cimetidine." Br Med J 298 (1989): 324-5
- Ziemniak JA, Bernhard H, Schentag JJ "Hepatic encephalopathy and altered cimetidine kinetics." Clin Pharmacol Ther 34 (1983): 375-82
- Lorenzini I, Jezequel AM, Orlandi F "Cimetidine-induced hepatitis: electron microscopic observations and clinical pattern of liver injury." Dig Dis Sci 26 (1981): 275-80
H2 Antagonists (Includes Leader Heartburn Relief) ↔ Gi Bleeding
Severe Potential Hazard, Moderate plausibility
Applies to: Gastrointestinal Hemorrhage
Histamine H2 receptor antagonists should not be used in the presence of vomit with blood, or bloody or black stools. These might be serious conditions and the diagnosis needs to be ruled out.
Cimetidine (Includes Leader Heartburn Relief) ↔ Hemodialysis
Moderate Potential Hazard, High plausibility
Applies to: hemodialysis
Cimetidine is partially removed by hemodialysis and should be administered after dialysis.
References
- Larsson R, Erlanson P, Bodemar G, Norlander B, Fransson L, Strouth L "Pharmacokinetics of cimetidine and its sulphoxide metabolite during haemodialysis." Eur J Clin Pharmacol 21 (1982): 325-30
- Bjaeldager PA, Jensen JB, Nielsen LP, Larsen NE, Hvidberg EF "Pharmacokinetics of cimetidine in patients undergoing hemodialysis." Nephron 34 (1983): 159-63
- "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
- Pizzella KM, Moore MC, Schultz RW, Walshe J, Schentag JJ "Removal of cimetidine by peritoneal dialysis, hemodialysis, and charcoal hemoperfusion." Ther Drug Monit 2 (1980): 273-81
Cimetidine (Includes Leader Heartburn Relief) ↔ Renal Dysfunction
Moderate Potential Hazard, High plausibility
Applies to: Renal Dysfunction
Cimetidine and its metabolites are primarily eliminated by the kidney. The daily dosage should initially be reduced in patients with moderate to severe renal impairment (CrCl < 50 mL/min). If necessary, the daily dosage may be increased with caution. Renal dysfunction also appears to be a risk factor for cimetidine-related central nervous system toxicity, which may include mental confusion, agitation, psychosis, depression, anxiety, hallucinations, and disorientation. These effects are generally reversible within 3 to 4 days after discontinuation of therapy.
References
- Larsson R, Bodemar G, Kagedal B "The effect of cimetidine, a new histamine H2-receptor antagonist, on renal function." Acta Med Scand 205 (1979): 87-9
- "Product Information. Tagamet (cimetidine)." SmithKline Beecham, Philadelphia, PA.
- Guay DR, Matzke GR, Bockbrader HN, Dancik J "Comparison of bioavailability and pharmacokinetics of cimetidine in subjects with normal and impaired renal function." Clin Pharm 2 (1983): 157-62
- Gladziwa U, Klotz U "Pharmacokinetic optimisation of the treatment of peptic ulcer in patients with renal failure." Clin Pharmacokinet 27 (1994): 393-408
- Larsson R, Norlander B, Bodemar G, Walan A "Steady-state kinetics and dosage requirements of cimetidine in renal failure." Clin Pharmacokinet 6 (1981): 316-25
- Larsson R, Erlanson P, Bodemar G, Walan A, Bertler A, Fransson L, Norlander B "The pharmacokinetics of cimetidine and its sulphoxide metabolite in patients with normal and impaired renal function." Br J Clin Pharmacol 13 (1982): 163-70
- Seidelin R "Cimetidine and renal failure." Postgrad Med J 56 (1980): 440-1
Leader Heartburn Relief (cimetidine) drug Interactions
There are 817 drug interactions with Leader Heartburn Relief (cimetidine)
Leader Heartburn Relief (cimetidine) alcohol/food Interactions
There are 3 alcohol/food interactions with Leader Heartburn Relief (cimetidine)
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No information available. |
Do not stop taking any medications without consulting your healthcare provider.
Disclaimer: Every effort has been made to ensure that the information provided by Multum is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. Multum's information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill, knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2018 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.
